ScinoPharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 11, 2023 at 07:27 am
Share
ScinoPharm Taiwan, Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was TWD 648.43 million compared to TWD 737.94 million a year ago. Net income was TWD 42.01 million compared to TWD 77.25 million a year ago.
Basic earnings per share from continuing operations was TWD 0.05 compared to TWD 0.1 a year ago. Diluted earnings per share from continuing operations was TWD 0.05 compared to TWD 0.1 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
